CAS: 3056-00-6; Laureth-12

上下游产品

聚醚醇 Polidocanol 3055-99-0
六乙二醇单十二醚 Hexaethylene Glycol Monododecyl Ether 3055-96-7
3-十二烷醇 2-[2-(2-Dodecyloxy-Ethoxy)-Ethoxy]-Ethanol 3055-94-5

📜六乙二醇单十二醚置于sodium Hydride体系中,用 四氢呋喃,Mineral Oil 用作溶剂,化学反应 5.0H,反应生成3,6,9,12,15,18,21,24,27,30,33,36-十二氧杂四十八烷-1-醇
参考文献:Application Of Monodisperse Pegs In Pharmaceutics: Monodisperse Polidocanols
标题:Application Of Monodisperse Pegs In Pharmaceutics: Monodisperse Polidocanols
摘要:Polydisperse Pegs Are Ubiquitously Used In Pharmaceutical Industry And Biomedical Research. However,The Monodispersity In Pegs May Play A Role In The Development Of Safe And Effective Pegylated Small Molecular Drugs. Here,To Avoid The Polydispersity In Polidocanol,The Active Ingredient In A Clinically Used Drug,A Macro Cyclic Sulfate-Based Strategy For The Efficient And Scalable Synthesis Of Monodisperse Polidocanols,Their Sulfates,And Their Methylated Derivatives,Was Developed. Tlc And HPLC Analysis Indicated A Complex Mixture In Regular Polidocanol And High Purifies In Monodisperse Polidocanols And Their Derivatives. Assay On Huvec,L929,And Hepg2. Cells Showed-That Monodisperse Polidocanols Have Much Higher Cytotoxicity And Safety Than That Of Regular Polidocanol. It Was Found That The Monodispersity Of Pegs In Polidocanols Is Crucial For Achieving The Optimal Therapeutic Results. Therefore,Based On This Case Study,It Would Be Beneficial To Optimize Pegylated Small Molecular Drugs With Monodisperse Pegs In Pharmaceutical Research And Development.
Doi:10.1021/acs.Molpharmaceut.7B00496

专利信息

专利号:US-2012094919-A1
优先权日:2009-03-16
标题 :Use of tripeptides
发明人：GRAEUB REMO; HEIDL MARC; IMFELD DOMINIK; MUELLER EIKE; WIKSTROEM PETER; ZIEGLER HUGO
权利人:GRAEUB REMO; HEIDL MARC; IMFELD DOMINIK; MUELLER EIKE; WIKSTROEM PETER; ZIEGLER HUGO
摘要:The present invention relates to the use of tripeptide derivatives for tightening, firming and/or moisturizing skin. Furthermore, the invention relates to a method for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue and/or proteoglycans by fibroblasts and/or keratinocytes such as in particular the synthesis of Hyaluronic acid and/or of the proteoglycans Decorin and/or Lumican.

专利号:US-12036300-B2
优先权日:2021-03-31
标题:Methods and compositions for improving skin
发明人：LIAO I-CHIEN; BRIEVA PATRICIA; JUCHAUX FRANCK; BOUEZ CHARBEL; ZHENG QIAN; QIAN KUN
权利人:OREAL
摘要:A method for managing skin tone comprising reducing the synthesis of melanin by applying a skin treatment composition to skin. The skin treatment composition may include about 0.1 to about 25 wt. % of acetyl trifluoromethylphenyl valylglycine; about 0.5 to about 30 wt. % of a polyol; about 0.1 to about 30 wt. % of a silicone, fatty compound, or a mixtures thereof, wherein the skin treatment composition is an emulsion, and all weight percentages are based on the total weight of the skin treatment composition.

专利号:EP-1493431-B1
优先权日:2003-07-03
标题:Use of an extract of bauhinia for the preparation of pharmaceutical and cosmetic compositions
发明人：WIRTH CORINNA DR; BUCHHOLZ HERWIG DR
权利人:MERCK PATENT GMBH
摘要:Use of an aqueous or aqueous-alcoholic extract (A) of Bauhinia is claimed to make a composition for cosmetic or pharmaceutical treatment of skin and hair. Use of an aqueous or aqueous-alcoholic extract (A) of Bauhinia is claimed to make a composition for: (a) care, preservation or improvement of the general condition of the skin or hair; (b) prevention and/or inhibition of the aging process for human skin or hair; (c) for promoting healing of wounds; (d) for prevention and/or treatment of skin diseases associated with abnormal keratinization, and (e) for prevention and/or treatment of all malignant or benign growths of the dermis or epidermis. An independent claim is also included for a composition containing (A). ACTIVITY : Dermatological; Vulnerary; Antiseborrheic; Antipsoriatic; Cytostatic; Antiinflammatory; Virucide. MECHANISM OF ACTION : Protein glycosylation inhibitor. In a test, human fibroblasts were cultured in the presence of Vitamin C to stimulate collagen synthesis, then lysed and labeled with tritiated glucose for 15 days, Proteins were removed, extraction and precipitation were carried and the amount of bound glucose measured by liquid scintillation counting. Addition of an aqueous-alcoholic extract of Bauhinia fortificata (0.03 mg/ml), reduced protein glycosylation to 55% of that in a control.